Choice Institutional Equities's report on Rainbow Childrens Medicare
Strategic network expansion through the hub-and-spoke model, deeper penetration into new markets and a sharper focus on tertiary and quaternary care are set to strengthen the growth trajectory. Additionally, the ongoing scale-up of the IVF vertical is expected to further propel strong and sustainable long-term growth. View and Valuation: We anticipate growth to be driven by strong momentum in IVF services, higher ARPOB and expansion into new geographies through organic and inorganic growth. We forecast Revenue/EBITDA/PAT to expand at a CAGR of 19.6%/22.0%/32.1% over FY25–FY28E.
Outlook
Valuing the stock at an EV/EBITDA multiple of 22x on the average of FY27 and FY28E, we maintain our target price of INR 1,685 and upgrade our rating to BUY (from ADD).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
